Welcome to LookChem.com Sign In|Join Free

Hubei Vanz Pharm Co.,Ltd

Diamond Supplier Enterprise Certification

Diamond
Supplier
6th
years
Home>>Products>>Dapagliflozin powder cas 461432-26-8

Product Certification&
Enterprise Certification

More Detail

Hubei Vanz Pharm Co.,Ltd

Country: China (Mainland)

Business Type:Trading Company

Ms.Chelsea gao

Tel: 86-27-84492310

Ms.Bella Li

Tel: 008618986076206

Ms.Chelsea Gao

Tel: +86 27 84492310

Ms.Wendy

Tel: WhatsApp +8615927784577

Ms.Mirriam

Tel: +8618071739296

Mobile: +8615207100586

Tel: 86-27-84492310

Fax: 86-27-84402310

URL: http://www.vanzpharm.com/en/index.html

Province/state: Hubei

City: JIAYU

Street: FANHU INDUSTRY PARK

MaxCard:


    x
  • Ms.Bella Li
  • Ms.Chelsea Gao
Contact Suppliers

Dapagliflozin powder cas 461432-26-8

CAS NO.461432-26-8

  • Min.Order: 1 Kilogram
  • Payment Terms: L/C,T/T,
Contact Supplier

Product Details

Keywords

  • Dapagliflozin
  • Dapagliflozin powder
  • 99% Dapagliflozin

Quick Details

  • ProName: Dapagliflozin powder cas 461432-26-8
  • CasNo: 461432-26-8
  • Molecular Formula: C21H25ClO6
  • Appearance: white
  • Application: Artemisia annua is used as antimalaria...
  • DeliveryTime: 7-10 days
  • PackAge: drum
  • Port: Shanghai/Wuhan
  • ProductionCapacity: 1000 Kilogram/Month
  • Purity: 99
  • Storage: room
  • LimitNum: 1 Kilogram

Superiority

Dapagliflozin  powder cas 461432-26-8 

Product Name:    Dapagliflozin
CAS:    461432-26-8
MF:    C21H25ClO6
MW:    408.88
EINECS:    639-683-0

 

Details

Dapagliflozin  powder cas 461432-26-8 

Product Name:    Dapagliflozin
CAS:    461432-26-8
MF:    C21H25ClO6
MW:    408.88
EINECS:    639-683-0 

Dapagliflozin It is also the first approved SGLT2 inhibitor for the treatment of type II diabetes, being an important option in the treatment of diabetes, and is used to improve glycemic control as an adjunct to dietary and exercise for adults with type II diabetes.
Dapagliflozin is   it for being used in the treatment of type II diabetes. Meanwhile, FDA requires the producers to conduct post-marketing research on drug-related risks.
The post-marketing trial requested by the FDA includes a cardiovascular outcome trial for assessing the cardiovascular risk for high-risk patients after treatment with dapagliflozin at baseline and a study to assess the risk of bladder cancer in recruited patients. Another study will assess the bladder tumor-promoting effect of this drug on rodent animals.